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INTRODUCTION
Many low-middle income countries, including in Asia, are now facing the intersection of
two epidemics-of communicable and non-communicable diseases, including diabetes
mellitus (DM) and tuberculosis (TB) specifically.1 DM has been recognised as an important
risk factor for TB in the general population, especially in the TB endemic settings.1,2 Poorly
controlled diabetics (with HbA1C>7%) are the main group at a higher risk of TB.1 Finally,
DM is also believed to elevate the risk of serious infections in general.3 Although the
mechanisms of these associations are not clear, they are thought to be directly related to
hyperglycemia and cellular insulinopenia, as well as indirect effects of hyperglycemia on
macrophage and lymphocyte function.1,3
HIV-positive individuals are at high risk of TB.4 Further, diabetes has emerged as one of the
important co-morbidities in HIV-positive individuals, especially in the antiretroviral therapy
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(ART) era.5,6 However, the relationship between blood glucose levels and TB in HIV
positive population has been remarkably understudied.7,8 Investigating this relationship in
HIV-positive individuals is important not only for better clinical management of HIV but
also for TB control in general. In this study, we model the relationship between fasting
blood glucose and risk of TB in the TREAT Asia HIV Observational Database (TAHOD), a
multi-country Asian cohort of HIV-positive individuals.
METHODS
Study population
TAHOD is a clinical cohort study of patients with HIV infection in Asia which began in
2003. The detailed methodology has been published elsewhere.9 Data are collected from 21
clinical sites in 12 countries and territories in Asia and transferred electronically to the Kirby
Institute every March and September. Ethical approval was obtained from the University of
New South Wales, Sydney, Australia, and all sites institutional review boards. For this
analysis, we included patients from TAHOD who had at least one glucose measurement, at
least 6 months of further follow-up, and no known TB at or before study entry.
Measurement of blood glucose
In TAHOD, blood glucose tests and results only started to be reported from a median year of
2008 (interquartile range (IQR): 2005-2010). Blood glucose values are measured according
to the local sites’ standard of care, and when measured, are captured during routine data
transfer. All values are expected to be measured after 8-12 hr fasting.
Outcome
The primary outcome was any diagnosis of TB, including both definitive and presumptive
diagnoses. The diagnostic criteria and the validation procedure used in TAHOD have been
published elsewhere.9, 10
Statistical analyses
We used Cox proportional hazard regression to model the relationship between glucose and
the outcome.11 Time at risk began at the first glucose measurement and ended at the
occurrence of the first event or lost to follow-up/death or censorship date of 31-
March-2013.The main exposure factors were baseline (at study entry) and time-updated
(latest) blood glucose which were categorised as deciles to assess for any non-linear
relationship with the incidence-rate of the outcome. We also analysed glucose as diabetic
range (≥7mmol/L as per American Diabetes association guidelines12) ever recorded in the
follow-up as the fixed variable. Models were adjusted for key risk factors10, which included
gender, reported injecting drug use (IDU) as mode of transmission, and age at study entry.
Time-updated covariates included CD4 count (categorised as <200, 200-350 and >350
cells/mm3), body mass index (BMI) defined as weight (kg)/height(m2) and categorised as
<18.5, 18.5-25, 25-30, >30 or missing, and receipt of ART. Once started, receipt of ART
was analysed as intention-to-treat. HIV viral load was not used in models due to concerns
about the missing data and collinearity. All time-updated variables were carried forward
when missing. Models were further stratified by clinical site, which also accounted for
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varying TB endemicity across the region. Recording of isoniazid primary prophylaxis is not
complete in TAHOD. Sensitivity analysis was conducted by either adjusting for or
excluding those who received isoniazid prophylaxis where known.
RESULTS
Of the potentially 8488 eligible patients, 4617 (19000 person-years of the follow-up) were
eligible for inclusion in the analysis. At cohort entry, those included (vs. excluded) were
more likely to be female, older, not reporting IDU and from a low TB burden country site as
defined by WHO.10, 13
At study entry, the mean age (standard deviation) was 38 (9.9) years, 67% were male, 5.4%
reported IDU, and 63% were from a high TB burden country. The median CD4 count was
269 (IQR: 140-430) cells/mm3, BMI was 21.4 (IQR: 19.3-23.7) kg/m2 (missing in 32%) and
glucose was 5 (IQR: 4.6-5.5) mmol/L. A vast majority (95.7%) started ART at some point in
the follow-up. Patients had a median (IQR) of 4 (2-8) glucose measurements, and the
median interval between glucose measurements was 5 (3-8) months.
There were 303 TB events at a rate of 1.58/100 person-years (95% confidence interval:
1.41-1.76). There was a U or inverse J-shaped relationship between the glucose (baseline or
latest) and the outcome, with the highest risk at both the extremes and the lowest risk at the
middle categories (Table-1). The risk was about 2-fold in the tenth decile (fasting blood
glucose of >6.5mmol/L) compared to the sixth decile (reference category). Baseline glucose
was a significant factor in both, unadjusted and adjusted models, stratified by site (Table-1).
Latest glucose also showed a similar trend and was a significant factor in unstratified models
(not shown), although the P-value for latest glucose became non-significant after stratifying
by site due possibly to loss of power11, 14. Further, occurrence of diabetic range of glucose
ever in the follow-up was also associated with the higher risk of TB in all models (Table-1).
Results were not sensitive to further adjustment or exclusion of those who were known to
have received INH prophylaxis (7.5% of participants) (not shown).
DISCUSSION
We found that higher levels of glucose are associated with the greater risk of TB. The effect
persisted even after analysing baseline or latest glucose levels, thereby minimising the
possibility of reverse causality (i.e. TB affecting the glucose) and suggest that high glucose
is likely to be associated with the prospective risk of TB.
Only a few other studies have assessed this relationship in HIV-positive individuals. Two
studies from India and Tanzania, respectively, found diabetes to be an important co-
morbidity in HIV-TB co-infected patients, although the HIV-positive individuals in these
studies were with lower CD4 count and not on ART.15, 16
Unexpectedly, we also found risk to be higher at the extreme low end of the measured
glucose. People with low glucose were also more likely to be with low BMI. The later
possibly reflects that the low glucose could be a marker of cachectic/undernourished state
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leading to or associated with TB. An undernourished state is known to be an important risk
factor for TB.17
There are limitations to our study. First, HbA1C, possibly a better marker of glucose control,
was not available in our cohort. Also, information about use of anti-diabetic medications or
formally validated information about diabetes diagnosis was not available. However, it
could be argued that higher risk of TB in diabetics is largely mediated by higher blood
glucose, which was measured in our study. Second, non-availability of blood glucose in all
participants could possibly lead to selection bias. Also, in this younger population, there
were only a few participants in the extreme categories of the glucose, possibly leading to
loss of power in some of the models. Glucose was not measured in a standardised fashion
and it is possible that for some patients it may not be a post-fasting level. Finally, important
variables such as smoking, diet details, and isoniazid prophylaxis were not available. These
limitations would likely cause bias toward the null and would underestimate relationships.
Our findings nevertheless need to be verified in larger studies.
Blood glucose control could play an important role in modifying the risk of TB in treated
HIV-positive individuals. Indeed, studies in general population from China and India have
suggested that more vigilant screening for TB in diabetics could be a worthwhile
approach.18-20 Future studies should investigate whether such an approach (and possibly
enhanced screening for DM in TB patients7, 19) in treated HIV-positive individuals further
improves clinical outcomes.
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